Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
WVE-006 Phase 2 Results Expected
WVE-006 • Alpha-1 Antitrypsin Deficiency
Target Indication
Alpha-1 Antitrypsin Deficiency
Clinical Trial
Last updated: 12/4/2025
WVE
Wave Life Sciences Ltd.
Duchenne Muscular Dystrophy
Huntington Disease